Learn how representations and warranties work in venture capital agreements, including company reps, investor reps, disclosure schedules, closing bring-down, survival, and securities-law risk.
Introduction
Representations and warranties in venture capital agreements are one of the most important legal tools for turning a negotiated term sheet into a real investment contract. In mainstream U.S. venture practice, the core financing package typically includes a certificate of incorporation, stock purchase agreement, investors’ rights agreement, voting agreement, and right of first refusal and co-sale agreement, and the NVCA’s current model documents continue to treat the Stock Purchase Agreement as a central financing document in that package. (nvca.org)
That matters because venture financing is not only about price, valuation, and dilution. It is also about factual risk. Investors want to know whether the company exists validly, whether it has authority to enter the deal, whether its capitalization is accurate, whether the stock being sold will be validly issued, whether material litigation exists, whether intellectual property is owned or licensed as represented, and whether the financing itself complies with applicable securities laws. The NVCA model Stock Purchase Agreement expressly identifies the company’s representations and warranties and the closing conditions as the main items of negotiation in the SPA. (nvca.org)
At the same time, investors make representations too. In private offerings, issuers commonly rely on investor representations about matters such as accredited-investor status, investment intent, and compliance with offering restrictions in order to support available exemptions from registration. SEC-filed subscription agreements routinely say that the company is relying on the truth and accuracy of those purchaser representations to determine the applicability of Securities Act and state-law exemptions. (SEC)
This is why representations and warranties in venture capital agreements are not filler. They are part of the legal machinery that prices risk, conditions closing, supports exempt-offering compliance, and allocates responsibility if statements turn out to be wrong. In a well-run deal, they are one of the clearest places where corporate law, contract law, and securities law all meet. (nvca.org)
What representations and warranties mean in VC practice
In venture practice, representations and warranties are usually negotiated together and appear as combined sections in the Stock Purchase Agreement. The NVCA model SPA describes the company as making representations and warranties to each purchaser and, separately, each purchaser as making representations and warranties to the company. That structure reflects how venture deals work in reality: the company is not the only party providing factual assurances. (nvca.org)
The practical role of these provisions is straightforward. They establish what facts are being treated as true for purposes of the deal and which facts each side is entitled to rely on in entering into the transaction. In the venture setting, this matters because the investor is usually buying preferred stock in a private company with limited public disclosure, while the company is relying on the investor’s status and intentions to fit within an exempt-offering framework. (SEC)
This also explains why reps and warranties are so heavily tied to the closing process. In the NVCA model SPA, the company’s representations and warranties, as modified by the disclosure schedule, must be true and correct as of closing, and that truth condition appears as part of the purchasers’ closing conditions. In other words, these provisions are not just background statements; they are part of what determines whether the investor has to close at all. (nvca.org)
Why they matter so much in venture deals
Representations and warranties matter in venture deals because startups are private, informationally uneven, and structurally complex. Investors are usually relying on management for accurate information about capitalization, contracts, technology, compliance, and litigation. The NVCA model SPA’s emphasis on company reps and closing conditions shows that market practice treats these provisions as a central risk-allocation device, not a drafting afterthought. (nvca.org)
They matter just as much from the company’s side. When the company is selling securities in a private placement, it needs a legally supportable path under the Securities Act. The SEC states that every offer and sale of securities must be registered or exempt, and private offerings under Regulation D often depend on investor status and other offering conditions. That is one reason investor representations about accredited-investor status, own-account investment, and offering compliance are so common. (SEC)
They also matter because exempt offerings are still subject to antifraud rules. The SEC states that private placements remain subject to the antifraud provisions of the federal securities laws and that information provided must not contain material misstatements or omit material facts necessary to make the statements made not misleading. So even in a private venture round, inaccurate company statements can create legal exposure well beyond contract claims. (SEC)
Where these provisions usually appear
In a standard preferred-stock venture round, the core set of representations and warranties usually appears in the Stock Purchase Agreement. NVCA’s model-document suite separately identifies the SPA from the charter, voting agreement, investors’ rights agreement, and ROFR/co-sale agreement, which underscores that the SPA is the main place where the immediate purchase-and-sale mechanics and factual assurances are negotiated. (nvca.org)
That division is deliberate. The certificate of incorporation generally handles the rights of the preferred stock itself, such as voting powers, preferences, and conversion features. Delaware law requires those powers, preferences, rights, and limitations to be stated in the certificate of incorporation or in properly authorized resolutions. The SPA, by contrast, is where the company and investors say, in effect, “Here are the facts we are relying on to do this financing now.” (delcode.delaware.gov)
This distinction is important for founders because it shows why reps and warranties should not be read in isolation. The SPA does not usually define the entire post-closing relationship. Instead, it works alongside the charter and the other venture documents, and its truth assumptions support the issuance of stock that must itself be valid under Delaware corporate law. (nvca.org)
Company representations and warranties: the core categories
The company-side representations in venture financings usually cover a familiar set of topics. The NVCA model SPA’s section list and related snippets show that these include, among other things, authorization, valid issuance of shares, governmental consents and filings, litigation, intellectual property, compliance with other instruments, and related core subjects. (nvca.org)
Organization, power, and authority
One of the first things investors want confirmed is that the company exists validly, is in good standing where relevant, and has the corporate power to enter into the financing. The NVCA model SPA includes an “Authorization” representation stating that the required corporate action of the board and stockholders to enter into the transaction agreements and issue the shares has been taken or will be taken before closing. Delaware law separately places the management of the corporation’s business and affairs in the board and requires the certificate of incorporation to authorize stock classes and rights. (nvca.org)
This is one of the most fundamental reps in the whole deal. If the company lacks authority, or if the board and stockholders have not properly approved the financing, the issuance itself can be compromised. In that sense, the representation is not just a comfort statement. It is directly tied to whether the company can lawfully do the transaction it is proposing to do. (nvca.org)
Capitalization and valid issuance
Investors also focus heavily on capitalization and valid issuance. The NVCA model SPA specifically includes “Valid Issuance of Shares” and related capitalization topics, and Delaware law provides that where a corporation is authorized to issue more than one class of stock, the certificate of incorporation must specify the classes and their powers, preferences, rights, and limitations. Delaware also recognizes the concept of “overissue,” including purported issuances in excess of authorized shares or issuances of a class or series not authorized by the certificate of incorporation. (nvca.org)
This is why capitalization reps are so important in venture financings. They help investors test whether the company’s cap table, stock authorizations, and issuance history are coherent. A bad capitalization representation is not just a diligence annoyance. It can signal that the corporation may have issued stock improperly or that the preferred shares now being sold may not sit cleanly in the capital structure. (nvca.org)
Governmental consents and securities-law compliance
The NVCA model SPA also includes a “Governmental Consents and Filings” representation. The relevant snippet indicates that, assuming the accuracy of purchaser representations, no additional governmental consent, approval, order, authorization, registration, qualification, designation, declaration, or filing is required on the company’s side other than specified filings, including securities-law filings made or to be made timely. (nvca.org)
This kind of representation matters because the financing itself is a securities offering. The SEC states that every offer and sale of securities must be registered or exempt, and Rule 506(b) private placements remain subject to specific conditions, including no general solicitation, investor-status requirements, and Form D notice filing. These are not abstract background rules. They are part of what the company is effectively representing it can comply with when it sells the shares. (SEC)
Litigation, compliance, and intellectual property
The NVCA model SPA’s section list also includes litigation, intellectual property, and compliance with other instruments. That reflects market reality. Investors want assurances that there is no undisclosed material litigation threatening the transaction, that the company’s IP position is consistent with the business being funded, and that the company is not materially violating its charter, bylaws, contracts, or other obligations in ways that would undermine enterprise value. (nvca.org)
These reps often do a great deal of practical work in startup deals. A software company with weak IP ownership, a life-sciences company with regulatory noncompliance, or a startup already in serious litigation may still be financeable, but not if those problems are hidden or misstated. The representation section is often where these risk areas are surfaced and then narrowed through the disclosure schedule. (nvca.org)
Disclosure schedules are where the real negotiation often happens
In venture financings, the company’s reps are rarely absolute. The NVCA model SPA states that the company represents and warrants “except as set forth on the Disclosure Schedule,” and that those exceptions are deemed part of the representations and warranties. It also states that the disclosure schedule should be arranged in sections corresponding to the numbered and lettered sections of the representation article. (nvca.org)
This is extremely important in practice. The disclosure schedule is where the company qualifies broad statements with specific facts. If the company has outstanding litigation, side letters, unusual contracts, IP exceptions, or capitalization irregularities that are not material enough to kill the deal but still need to be disclosed, the schedule is usually where they appear. In other words, the representation section says what is generally true, and the disclosure schedule says where reality deviates. (nvca.org)
For founders, this means the schedule is not clerical. It is often the difference between a false rep and a qualified, accurate rep. For investors, it is one of the most useful diligence documents in the transaction because it translates abstract warranties into a list of concrete exceptions. (nvca.org)
Investor representations and warranties: why they matter
The investors make representations too, and those are not just formalities. The NVCA model SPA includes a separate article titled “Representations and Warranties of the Purchasers,” including items such as authorization, restricted-securities understanding, accredited-investor status, foreign-investor matters, and no general solicitation by the purchaser. (nvca.org)
Authorization and enforceability
The investor typically represents that it has the authority to enter into the transaction documents and that those documents are binding on it, subject to standard bankruptcy and equitable-remedies qualifications. This is the mirror image of the company’s authorization reps. The company wants to know that the investor is legally capable of closing, funding, and performing. (nvca.org)
Purchase for own account and restricted-securities understanding
The NVCA model SPA includes “Purchase Entirely for Own Account” language and a “Restricted Securities” representation. The snippets show that purchasers represent that they are acquiring the shares for investment for their own account and not with a present intention to resell or distribute them, and that they understand the shares are not registered under the Securities Act and are being sold in reliance on a specific exemption. (nvca.org)
These representations matter because private-placement exemptions depend in part on the nature of the transaction and the investment intent of the buyer. They also help support the restricted-security status of the stock and create a record that the purchaser understood the resale limitations and private-placement context. (SEC)
Accredited investor and foreign-investor reps
The NVCA model SPA also includes an “Accredited Investor” representation, under which the purchaser states it is an accredited investor as defined in Rule 501(a) of Regulation D. It also includes a foreign-investor representation addressing the purchaser’s own compliance with its local law and related restrictions if it is not a U.S. person. (nvca.org)
These reps matter because the issuer’s Regulation D pathway may depend on them. The SEC states that certain exempt offerings may only be offered to or purchased by accredited investors and that investor status is central to the exempt-offering framework. A company selling in reliance on private-placement exemptions is therefore not being overly cautious when it asks for detailed investor reps. It is building the legal basis for the exemption record. (SEC)
No general solicitation and exemption support
The NVCA model SPA also includes a purchaser representation that the purchaser and its affiliates have not engaged in general solicitation or published advertisements in connection with the offer and sale of the shares. That aligns with the SEC’s Rule 506(b) regime, which prohibits general solicitation in offerings relying on that safe harbor. (nvca.org)
This is another example of how investor reps do real legal work. They are not just there for completeness. They support the company’s ability to say the round was conducted within the conditions of the claimed exemption. (nvca.org)
Closing bring-down: why truth at signing is not enough
One of the most important practical features of representations and warranties in VC deals is the bring-down at closing. The NVCA model SPA provides that the company’s representations and warranties, as modified by the disclosure schedule, must be true and correct in all respects as of the initial closing, and it makes that truth condition part of the purchasers’ closing conditions. SEC-filed subscription agreements also commonly state that issuer reps are made both as of the signing date and as of the closing date. (nvca.org)
This matters because a venture deal often has a gap between signing and closing, or even multiple closings. Investors do not want to be locked into a transaction if a material fact changes in the meantime. The bring-down concept is therefore a bridge between factual accuracy and closing risk. If a key representation ceases to be true, the investor may have a basis not to close, or at least to require a disclosure-schedule update or renegotiation. (nvca.org)
The same logic appears on the investor side in private-placement practice. SEC-filed subscription agreements commonly state that the subscriber’s representations are true at execution and will also be true as of the closing date. That symmetry is important because offering-exemption reliance does not become irrelevant just because the investor signed earlier. (SEC)
Survival: what happens after the closing
Representations and warranties do not always disappear when the wire hits. The NVCA model SPA states that, unless otherwise set forth in the agreement, the representations and warranties of the company and the purchasers survive execution, delivery, and the closing, and are not affected by investigation or knowledge by either side. SEC-filed private-placement agreements likewise commonly include survival provisions stating that the reps, warranties, covenants, and agreements survive closing. (nvca.org)
Survival matters because it preserves the legal significance of the statements after the transaction closes. In practical terms, it means that if a representation was false and the agreement provides a remedy, the party that relied on it may still have a post-closing claim. The exact duration and remedy structure are deal-specific, but the concept itself is standard enough that both the NVCA model and SEC-filed private-placement agreements show it prominently. (nvca.org)
Indemnity and remedy: narrower in classic VC than many founders assume
In venture financings, remedy structure is often narrower and more selective than founders expect from M&A practice. The NVCA model SPA prominently emphasizes reps, warranties, and closing conditions, and it includes specific indemnity language at least for finder’s-fee exposure, with each side agreeing to indemnify the other for broker or finder claims attributable to that side. At the same time, the model also acknowledges that certain indemnification provisions may be limited by applicable federal or state securities laws. (nvca.org)
That is an important practical point. In classic venture deals, the SPA is not always built like a private-company acquisition agreement with a sprawling, heavily negotiated post-closing indemnity regime for every representation breach. The legal emphasis is often on getting the facts right, qualifying them through the disclosure schedule, conditioning closing on their truth, and preserving survival language. Remedy structure still matters, but in market practice it is often more targeted than founders assume. (nvca.org)
Securities-law overlay: reps and warranties do not replace anti-fraud rules
One of the most important legal points is that contractual reps and warranties do not displace securities law. The SEC states that all securities transactions, including exempt offerings, remain subject to the antifraud provisions of the federal securities laws and that information provided must not contain material misstatements or omit material facts necessary to prevent the statements made from being misleading. (SEC)
This means a company cannot solve a misleading fundraising presentation just by drafting broad contractual disclaimers. Nor can an investor avoid reality by signing boilerplate acknowledgments if the offering materials are materially false. Reps and warranties matter, but they sit inside a broader securities-law regime in which private placements remain regulated and misleading statements can create enforcement and litigation exposure. (SEC)
It also explains why investor reps are drafted so carefully in private placements. SEC-filed subscription agreements repeatedly state that the issuer is relying on the truth and accuracy of the subscriber’s representations to determine the applicability of Securities Act and state-law exemptions. Those contractual statements and the securities-law framework reinforce each other. (SEC)
Common founder mistakes around reps and warranties
The first common mistake is to treat the representation section as boilerplate and focus only on valuation. That is backward. The NVCA model SPA specifically identifies company reps and closing conditions as the main items of negotiation in the SPA. A founder who assumes the disclosure schedule can be cleaned up casually later is usually underestimating where the real deal risk lives. (nvca.org)
The second mistake is to overstate or oversimplify facts in diligence and then hope the contract will smooth things over. It will not. The SEC’s antifraud framework still applies, and the disclosure schedule exists precisely because nuanced reality needs to be disclosed rather than buried. (SEC)
The third mistake is to ignore purchaser-side reps as if they were only investor paperwork. In private offerings, those reps often support the issuer’s exemption analysis. If the company does not collect them carefully, it may weaken its own compliance position. (SEC)
Conclusion
Representations and warranties in venture capital agreements are a central part of how private-company financings actually work. In standard U.S. venture practice, they live primarily in the Stock Purchase Agreement, where the company and the investors each make factual assurances that support pricing, closing, and legal compliance. The NVCA model documents show that these provisions are among the main items of negotiation in the SPA, and both venture-market practice and SEC-filed private-placement agreements show that disclosure schedules, closing bring-downs, and survival clauses are all part of the normal architecture. (nvca.org)
For founders, the lesson is that the representation package is not secondary to the deal. It is part of the deal. For investors, the lesson is that contractual assurances still sit inside a larger framework of corporate validity, offering-exemption compliance, and antifraud liability. In venture capital, representations and warranties do not just describe reality. They are one of the main legal devices through which the parties decide which version of reality the financing is entitled to rely on. (delcode.delaware.gov)
Frequently Asked Questions
What are representations and warranties in a venture capital agreement?
They are factual assurances made by the company and the investors in the financing documents, usually the Stock Purchase Agreement, about matters the parties are relying on to enter into the transaction. The NVCA model SPA uses combined “Representations and Warranties” sections for both the company and the purchasers. (nvca.org)
Why do investors care so much about company reps and warranties?
Because the NVCA model SPA identifies them, along with closing conditions, as the main items of negotiation in the SPA, and they help investors assess legal, corporate, capitalization, compliance, and business risk before closing. (nvca.org)
What is the purpose of the disclosure schedule?
The disclosure schedule qualifies the company’s reps by listing exceptions. The NVCA model SPA states that the company reps are made except as set forth on the disclosure schedule and that those exceptions are deemed part of the representations and warranties. (nvca.org)
Do investor reps really matter in private placements?
Yes. SEC-filed subscription agreements commonly state that the issuer is relying on the truth and accuracy of investor representations to determine whether exemptions from registration under the Securities Act and state law are available. (SEC)
Are representations and warranties only relevant at signing?
No. The NVCA model SPA makes the truth of company reps a closing condition, and SEC-filed private-placement agreements commonly say issuer and investor reps are made both at signing and at closing. (nvca.org)
Do contractual reps and warranties eliminate securities-law fraud risk?
No. The SEC states that exempt offerings remain subject to the antifraud provisions of the federal securities laws and that information provided must not contain material misstatements or material omissions. (SEC)
Yanıt yok